NNVCライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:51):

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections...

Stats
本日の出来高	5 699.00
平均出来高	36 373.00
時価総額	12.96M
EPS	$0 ( 2024-02-14 )
次の収益日	( $-0.190 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.370
ATR14	$0.0100 (0.91%)

Insider Trading

Date	Person	Action	Amount	type
2022-08-08	Diwan Anil	Sell	94 471	Common Stock, par value $0.001 per share
2020-02-07	Jawadakar Makarand	Buy	0
2019-06-02	Day Mark D.	Buy	0
2018-05-21	Boniuk Milton	Buy	5 500 000	Common Stock, par value $0.001 per share
2017-02-21	Boniuk Milton	Buy	1 746 288	Common Stock, par value $0.001 per share

INSIDER POWER
-100.00
Last 95 transactions
Buy: 11 406 507 \| Sell: 1 435 933

NanoViricides Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

NanoViricides Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2023
収益:	$0
総利益:	$-747 529 (0.00 %)
EPS:	$-0.740

FY	2022
収益:	$0
総利益:	$-723 325 (0.00 %)
EPS:	$-0.700

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

NanoViricides Inc

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.